 |
| 13-Mar-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$19 → $16 |
|
| 13-Mar-13 | Downgrade |
WallachBeth |
Buy → Sell |
$20 → $5.50 |
|
| 02-May-11 | Reiterated |
MLV Capital |
Buy |
$12.50 → $20.50 |
|
| 25-Mar-11 | Initiated |
RBC Capital Mkts |
Outperform |
$12 |
|
| 07-Dec-10 | Reiterated |
Morgan Joseph |
Buy |
$8 → $10 |
|
| 12-Jan-10 | Upgrade |
Morgan Joseph |
Hold → Buy |
$8 |
|
| 14-Oct-09 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$10 → $8 |
|
| 08-Sep-09 | Downgrade |
Morgan Joseph |
Buy → Hold |
|
|
| 09-Sep-08 | Initiated |
Morgan Joseph |
Buy |
$5 |
|
| 23-Apr-08 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 18-Mar-08 | Downgrade |
Brean Murray |
Buy → Hold |
|
|
| 01-Nov-07 | Reiterated |
Friedman Billings |
Mkt Perform |
$5.50 → $4 |
|
| 31-Oct-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$8 → $6 |
|
| 09-Oct-07 | Upgrade |
Brean Murray |
Hold → Buy |
$11 |
|
| 25-Jul-07 | Upgrade |
Brean Murray |
Sell → Hold |
|
|
| 25-Jul-07 | Reiterated |
Lazard Capital |
Buy |
$11 → $6 |
|
| 25-Jul-07 | Downgrade |
Friedman Billings |
Outperform → Mkt Perform |
$12.25 → $5.50 |
|
| 23-Jul-07 | Downgrade |
Brean Murray |
Buy → Sell |
$11 → $4 |
|
| 24-May-07 | Initiated |
Friedman Billings |
Outperform |
$12.25 |
|
| 11-Apr-07 | Initiated |
Brean Murray |
Buy |
$11 |
|
|
|
| 20-May-13 11:03PM | SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online |
| 06:40PM | Spectrum Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:30 PM at Seeking Alpha |
| 06:40PM | Spectrum Pharmaceuticals' CEO Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha |
| 17-May-13 02:20PM | Outlook for the Most Shorted Stocks at Motley Fool |
| 01:04PM | SPECTRUM PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 07:00AM | The 5 Dumbest Things on Wall Street This Week: May 17 at TheStreet |
| 07:00AM | Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma at TheStreet |
| 05:30AM | [video] 5 Dumbest Things on Wall Street at TheStreet |
| 14-May-13 11:58PM | Spectrum Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha |
| 09:30AM | Spectrum Pharma Reports 1Q Loss Zacks |
| 13-May-13 01:39PM | 4 Obscure Healthcare Stocks To Watch In 2013 at Seeking Alpha |
| 07:19AM | SEC Is Investigating Spectrum Pharma at TheStreet |
| 07:00AM | Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th Business Wire |
| 11-May-13 09:32AM | 3 Investment Strategy Lessons From Vertex's Success at Motley Fool |
| 10-May-13 02:05PM | 5 Stocks Poised to Break Out at TheStreet |
| 07:00AM | Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th Business Wire |
| 09-May-13 05:00PM | Spectrum Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 07:07AM | Q1 2013 Spectrum Pharmaceuticals Inc Earnings Release - Before Market Open CCBN |
| 07:00AM | Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013 Business Wire |
| 12:02AM | SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online |
| 08-May-13 09:07AM | Two Different Outlooks With Similar Growth Plans at Motley Fool |
| 07-May-13 02:42PM | SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position PR Newswire |
| 03-May-13 05:45PM | The Nasdaq's 5 Most Hated Stocks at Motley Fool |
| 02:20PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of the Class Action Lawsuit and Upcoming Deadline -- SPPI GlobeNewswire |
| 02-May-13 07:00AM | Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast Business Wire |
| 30-Apr-13 05:21PM | DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Upcoming Deadline Business Wire |
| 09:37AM | Deadline on May 13, 2013 in Lawsuit for Investors in Spectrum Pharmaceuticals, Inc. (SPPI) Announced by Shareholders Foundation GlobeNewswire |
| 28-Apr-13 02:00PM | Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. Business Wire |
| 07:52AM | Growth Opportunities but Uncertainty Around Core Drug at Motley Fool |
| 26-Apr-13 07:14AM | SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position Business Wire |
| 23-Apr-13 09:30AM | 21 Days Remain before May 13, 2013, Lead Plaintiff Deadline in Investor Lawsuit against Spectrum Pharmaceuticals, Inc. Business Wire |
| 19-Apr-13 01:34PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- SPPI GlobeNewswire |
| 18-Apr-13 02:21PM | The O'Mara Law Firm Files Class Action Suit Against Spectrum Pharmaceuticals, Inc. and Reminds Investors of Lead Plaintiff Deadline GlobeNewswire |
| 17-Apr-13 02:20PM | Tackling Cancer: Non-Hodgkin Lymphoma's Biggest Current & Upcoming Players at Motley Fool |
| 12-Apr-13 09:01PM | Law Offices of Todd M. Garber Announces Investigation of Spectrum Pharmaceuticals, Inc. Business Wire |
| 11-Apr-13 10:06AM | Saxena White P.A. Files Securities Fraud Class Action Against Spectrum Pharmaceuticals, Inc. Marketwired |
| 10:06AM | Saxena White P.A. Files Securities Fraud Class Action Against Spectrum Pharmaceuticals, Inc. Marketwire |
| 10-Apr-13 01:56PM | Tackling Cancer: Bladder Cancer's Biggest Current & Upcoming Players at Motley Fool |
| 09-Apr-13 04:10PM | Spectrum Progresses with SPI-2012 Zacks |
| 08-Apr-13 07:00AM | Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia Business Wire |
| 06-Apr-13 04:30PM | The Nasdaq's 5 Most Hated Stocks at Motley Fool |
| 05-Apr-13 09:08PM | Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. Business Wire |
| 06:55PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- SPPI GlobeNewswire |
| 04-Apr-13 06:44PM | SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position Marketwired |
| 06:44PM | SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position Marketwire |
| 03-Apr-13 09:30AM | Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit Business Wire |
| 01-Apr-13 02:16PM | Can Spectrum Pharmaceuticals Regain Investor Trust? at Seeking Alpha |
| 10:05AM | Does Spectrum's Q4 Earnings Make It a Buy? at Motley Fool |
| 31-Mar-13 01:30PM | 3 Biggest Biotech Crashes This Month at Motley Fool |
| 29-Mar-13 08:30PM | Glancy Binkow & Goldberg LLP Announces Filing of a Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. Business Wire |
| 06:45PM | Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 From Investment in Spectrum Pharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the May 13, 2013 Lead Pla GlobeNewswire |
| 28-Mar-13 04:07AM | S&P 1500 Most Heavily Shorted Stocks at Seeking Alpha |
| 26-Mar-13 01:26PM | Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. Business Wire |
| 25-Mar-13 07:15PM | 2 Big Risks Threatening Celgene at Motley Fool |
| 12:57PM | SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Spectrum Pharmaceuticals, Inc. and Certain Officers -- SPPI GlobeNewswire |
| 23-Mar-13 07:47PM | 5 Stocks To Watch For Gains This Week at Seeking Alpha |
| 22-Mar-13 07:00PM | Gainey McKenna & Egleston Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. -- SPPI GlobeNewswire |
| 02:16PM | CORRECTING and REPLACING Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against Spectrum Pharmaceuticals, Inc. Business Wire |
| 12:28PM | Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against Spectrum Pharmaceuticals, Inc. Business Wire |
| 11:15AM | Lifshitz Law Firm Announces Investigation of Navistar International Corporation, Spectrum Pharmaceuticals, Inc., and Tech Data Corporation PR Newswire |
| 09:30AM | Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline Business Wire |
| 21-Mar-13 07:50PM | Spectrum Pharmaceuticals, Inc. Sued by Shareholders PR Newswire |
| 12:49PM | 3 Stocks with More than 50% Short Interest at Motley Fool |
| 10:46AM | Spectrum Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire |
| 20-Mar-13 03:03PM | Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall at Seeking Alpha |
| 09:35AM | Lawsuit on Behalf of Spectrum Pharmaceuticals, Inc. (SPPI) Investors Announced by Shareholders Foundation GlobeNewswire |
| 08:33AM | Spectrum Faces Questions and 3 Stocks at 52-Week Lows at Wall St. Cheat Sheet |
| 05:00AM | Spectrum Pharmaceuticals Inc Stock Downgraded (SPPI) at TheStreet |
| 19-Mar-13 04:52PM | Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc. PR Newswire |
| 08:39AM | Spectrum Pharmaceuticals Gets New Leadership and 2 Stocks At 52-Week Lows at Wall St. Cheat Sheet |
| 18-Mar-13 05:48PM | SPPI Acquires Late-Stage Candidate Zacks |
| 03:59PM | SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of May 13, 2013 to Seek a Lead Plaintiff Position -- SPPI GlobeNewswire |
| 08:03AM | InPlay: Spectrum Pharma appoints Lee Allen as Chief Medical Officer Briefing.com |
| 07:02AM | Spectrum names Lee F. Allen as Chief Medical Officer at theflyonthewall.com |
| 07:00AM | Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer Business Wire |
| 17-Mar-13 05:30AM | 5 of Last Week's Biggest Losers at Motley Fool |
| 16-Mar-13 12:00PM | This Week in Biotech at Motley Fool |
| 11:09AM | Ulta Salon Sees Choppy Waters and 2 Stocks At 52-Week Lows at Wall St. Cheat Sheet |
| 05:00AM | Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. Business Wire |
| 15-Mar-13 04:16PM | Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. Business Wire |
| 03:30PM | Ryan & Maniskas, LLP Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. PR Newswire |
| 11:48AM | Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Marketwire |
| 07:52AM | 5 Dumbest Things on Wall Street This Week: March 15 at TheStreet |
| 07:00AM | Spectrum Pharmaceuticals to Present Corporate Update at the 25th Annual ROTH Conference in Laguna Niguel on March 20th Business Wire |
| 05:00AM | [video] The 5 Dumbest Things on Wall Street: March 15 at TheStreet |
| 14-Mar-13 10:20PM | Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Spectrum Pharmaceuticals, Inc. Business Wire |
| 06:33PM | Picking Up the Pieces of Shattered Spectrum at Motley Fool |
| 05:00PM | 4 Healthcare Stock Stories to Ignite Investor Chatter at Wall St. Cheat Sheet |
| 03:03PM | Fusilev Unravels Spectrum's Revenue Growth, Bears Descend On Company at Seeking Alpha |
| 01:45PM | S&P 1500's Most Heavily Shorted Stocks at Seeking Alpha |
| 01:32PM | Nasdaq stocks posting largest percentage decreases AP |
| 01:14PM | Spectrum licenses Ligand multiple myeloma drug AP |
| 10:36AM | Has Spectrum Pharmaceuticals Become the Perfect Stock? at Motley Fool |
| 09:14AM | Wall Street to tick up at open, Dow may rise for 10th day Reuters |
| 08:38AM | S&P 500 futures add to gains after data Reuters |
| 08:11AM | Stock futures tick up ahead of claims, prices data Reuters |
| 07:08AM | Spectrum gains rights to Capitsol-enabled Melphalan theflyonthewall.com |
| 07:01AM | SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online |
| 07:00AM | Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan Business Wire |
| 13-Mar-13 10:26PM | Here's What This $41 Billion Hedge Fund Company Has Been Buying at Motley Fool -37.33% |
|
|
| Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company’s oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MAIDA ANTHONY E III | Director | Mar 05 | Option Exercise | 3.92 | 5,000 | 19,600 | 12,550 | Mar 05 03:38 PM | | MAIDA ANTHONY E III | Director | Mar 05 | Sale | 11.50 | 5,000 | 57,499 | 7,550 | Mar 05 03:38 PM | | MAIDA ANTHONY E III | Director | Feb 05 | Option Exercise | 4.14 | 5,000 | 20,722 | 5,550 | Feb 06 03:53 PM | | MAIDA ANTHONY E III | Director | Feb 05 | Sale | 12.25 | 5,000 | 61,245 | 2,250 | Feb 06 03:53 PM | | MAIDA ANTHONY E III | Director | Jan 02 | Option Exercise | 4.26 | 5,000 | 21,300 | 7,250 | Jan 02 06:30 PM | | MAIDA ANTHONY E III | Director | Jan 02 | Sale | 11.42 | 5,000 | 57,109 | 2,250 | Jan 02 06:30 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Dec 31 | Sale | 11.24 | 205,836 | 2,313,267 | 1,484,106 | Jan 02 06:32 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Dec 28 | Sale | 11.35 | 172,507 | 1,957,954 | 1,689,942 | Jan 02 06:32 PM | | MAIDA ANTHONY E III | Director | Dec 04 | Option Exercise | 4.26 | 5,000 | 21,300 | 7,250 | Dec 04 05:32 PM | | MAIDA ANTHONY E III | Director | Dec 04 | Sale | 11.65 | 5,000 | 58,265 | 2,250 | Dec 04 05:32 PM | | Keller Joseph Kenneth | EVP & Chief Operating Officer | Nov 12 | Buy | 10.95 | 10,000 | 109,469 | 138,000 | Nov 13 01:54 PM | | MAIDA ANTHONY E III | Director | Nov 01 | Option Exercise | 3.13 | 5,000 | 15,657 | 5,550 | Nov 02 04:45 PM | | MAIDA ANTHONY E III | Director | Nov 01 | Sale | 11.09 | 5,000 | 55,439 | 2,250 | Nov 02 04:45 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Oct 09 | Sale | 12.50 | 11,350 | 141,875 | 2,316,916 | Oct 11 06:45 PM | | MAIDA ANTHONY E III | Director | Oct 02 | Option Exercise | 6.65 | 5,000 | 33,250 | 7,250 | Oct 03 02:37 PM | | MAIDA ANTHONY E III | Director | Oct 02 | Sale | 11.80 | 5,000 | 59,009 | 2,250 | Oct 03 02:37 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Sep 20 | Sale | 12.50 | 4,800 | 60,000 | 2,328,134 | Sep 20 05:43 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Sep 19 | Sale | 12.74 | 33,000 | 420,394 | 2,332,934 | Sep 20 05:43 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Sep 18 | Sale | 13.02 | 33,000 | 429,591 | 2,365,934 | Sep 20 05:43 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Sep 06 | Sale | 12.63 | 34,000 | 429,335 | 2,398,934 | Sep 07 07:39 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Sep 05 | Sale | 12.53 | 33,000 | 413,573 | 2,432,934 | Sep 07 07:39 PM | | MAIDA ANTHONY E III | Director | Sep 04 | Option Exercise | 6.65 | 5,000 | 33,250 | 7,250 | Sep 06 05:03 PM | | MAIDA ANTHONY E III | Director | Sep 04 | Sale | 12.01 | 5,000 | 60,040 | 2,250 | Sep 06 05:03 PM | | Krassner Stuart Mitchell | Director | Aug 17 | Sale | 12.58 | 5,750 | 72,335 | 0 | Aug 20 05:10 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Aug 16 | Sale | 12.61 | 84,000 | 1,058,887 | 2,465,934 | Aug 16 04:54 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Aug 15 | Sale | 12.54 | 83,000 | 1,040,447 | 2,549,934 | Aug 16 04:54 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Aug 14 | Sale | 12.53 | 41,500 | 519,995 | 2,632,934 | Aug 16 04:54 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Aug 09 | Option Exercise | 1.06 | 75,000 | 79,163 | 2,674,434 | Aug 10 12:12 PM | | Krassner Stuart Mitchell | Director | Jul 13 | Sale | 16.47 | 5,000 | 82,370 | 5,750 | Jul 16 01:27 PM | | SHROTRIYA RAJESH C MD | Chairman, CEO & President | Jul 12 | Option Exercise | 1.47 | 68,027 | 100,000 | 2,605,870 | Jul 12 05:27 PM |
|
|
|
|
|
|
